Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

The deal includes two recently approved GSK products for metastatic ... The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new ...

The global sore throat lozenges market is projected to be valued at USD 4.4 billion in 2024 and is expected to grow at a CAGR of 5.6%, reaching an estimated value of approximately USD 7.5 billion by ...

As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company. We believe ...

Thailand Pharmaceutical Industry, according to Fitch Solutions, the pharmaceutical market in Southeast Asia has a market size ...

GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture ... of Horlicks and other consumer healthcare nutrition products to fund the acquisition, after saying last ...

We think sales of Spinraza (partnered with Ionis) will remain around $2 billion, although competition from Novartis (gene therapy ... and ongoing potential for product governance issues (including ...

Also this month, it transferred its OTC (over the counter) business into its wholly-owned consumer products subsidiary. Majumdar did not go so far, as to forecast a similar future for the ...

Detailed price information for Argo Living Soils Corp (ARGO-CN) from The Globe and Mail including charting and trades.